Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Cash flows from operating activities:
Net income	$ 18,143	$ 16,113	$ 47,184
Adjustments to reconcile to net cash provided by operating activities:
Stock-based compensation expense	11,115	10,739	7,063
Depreciation and amortization	11,197	9,355	5,990
Deferred income taxes	3,383	20,188	9,229
Non-cash development expenses from joint venture	3,670	5,290	5,995
Impairment of in-process research and development	9,600	0	0
Impairment of long-lived assets	0	976	1,218
Change in fair value of contingent value rights	(3,005)	221	0
Provision for impairment of accrued interest on note receivable	0	0	1,032
Excess tax benefits from stock-based compensation	(1,588)	(4,608)	(2,609)
Other	(40)	392	(38)
Changes in operating assets and liabilities:
Accounts receivable	(21,890)	(34,873)	19,094
Inventories	(500)	(1,939)	799
Income taxes	8,055	1,422	(4,454)
Prepaid expenses and other assets	(1,038)	660	(764)
Accounts payable	274	2,510	3,392
Accrued expenses and other liabilities	169	(95)	(447)
Accrued compensation	1,649	(3,303)	6,175
Deferred revenue	449	(10,863)	(838)
Net cash provided by operating activities	39,643	12,185	98,021
Cash flows from investing activities:
Purchases of property, plant and equipment	(53,845)	(54,026)	(22,101)
Proceeds from sale of assets	11,765	0	0
Proceeds from maturity of investments	1,966	4,250	6,518
Purchase of investments	0	(4,187)	0
Acquisition of Trubion Pharmaceuticals, Inc., net of cash acquired	0	0	(17,873)
Repayment of note receivable	0	0	10,000
Net cash used in investing activities	(40,114)	(53,963)	(23,456)
Cash flows from financing activities:
Proceeds from borrowings on long-term indebtedness	13,547	27,522	15,000
Issuance of common stock subject to exercise of stock options	761	10,026	7,235
Excess tax benefits from stock-based compensation	1,588	4,608	2,609
Principal payments on long-term indebtedness and line of credit	(10,227)	(15,494)	(33,291)
Contingent value right payment	(1,748)	(10,000)	0
Purchase of treasury stock	(5,906)	0	0
Restricted cash deposit	220	(3)	(2)
Net cash provided by (used in) financing activities	(1,765)	16,659	(8,449)
Effect of exchange rate changes on cash and cash equivalents	1	1	(21)
Net increase (decrease) in cash and cash equivalents	(2,235)	(25,118)	66,095
Cash and cash equivalents at beginning of year	143,901	169,019	102,924
Cash and cash equivalents at end of year	141,666	143,901	169,019
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	2,137	1,740	2,176
Cash paid during the year for income taxes	6,537	4,280	22,440
Supplemental information on non-cash investing and financing activities:
Issuance of common stock to acquire Trubion Pharmaceuticals, Inc.	0	0	61,203
Purchases of property, plant and equipment unpaid at year end	$ 5,612	$ 15,509	$ 3,519